Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4726-4732

  Alexander, Louis ^a   Zhang, Sharon ^a   McAuliffe, Brian ^a   Connors, David ^a   Zhou, Nannon ^a   Wang, Tao ^a   Agler, Michele ^a   Kadow, John ^a   Lin, Pin Fang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; PLERIXAFOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MIXED LYMPHOCYTE CULTURE; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS STRAIN;

ANTI-HIV AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; RECEPTORS, CXCR4; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS ATTACHMENT;

EID: 70350279551     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00494-09     Document Type: Article

References (58)

1. + count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22:841-848.
2. Barretina, J., J. Blanco, M. Armand-Ugon, A. Gutierrez, B. Clotet, and J. A. Este. 2003. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir. Ther. 8:155-161.
3. Berkowitz, R. D., S. Alexander, C. Bare, V. Linquist-Stepps, M. Bogan, M. E. Moreno, L. Gibson, E. D. Wieder, J. Kosek, C. A. Stoddart, and J. M. McCune. 1998. CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J. Virol. 72:10108-10117.
4. Blanco, J., J. Barretina, G. Henson, G. Bridger, E. De Clercq, B. Clotet, and J. A. Este. 2000. The CXCR4 antagonist AMD3100 efficiently inhibits cellsurface- expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob. Agents Chemother. 44:51-56.
5. Briggs, J. A., M. C. Johnson, M. N. Simon, S. D. Fuller, and V. M. Vogt. 2006. Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus. J. Mol. Biol. 355:157-168.
6. Brumme, Z. L., J. Goodrich, H. B. Mayer, C. J. Brumme, B. M. Henrick, B. Wynhoven, J. J. Asselin, P. K. Cheung, R. S. Hogg, J. S. Montaner, and P. R. Harrigan. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192:466-474.
7. Dimitrov, D. S., R. L. Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:2182-2190. (Pubitemid 23088394)
8. + T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1. J. Virol. 75:1152-1164.
9. Este, J. A., and A. Telenti. 2007. HIV entry inhibitors. Lancet 370:81-88.
10. Fauci, A. S., S. M. Schnittman, G. Poli, S. Koenig, and G. Pantaleo. 1991. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 114:678-693.
11. Geleziunnas, R., W. Xu, K. Takeda, H. Ichijo, and W. C. Greene. 2001. HIV-1 Nef inhibits ASK-1 dependent death signaling providing a potential mechanism for protecting the infected host cell. Nature 410:834-838.
12. + T cell recovery with antiretroviral therapy: more than the sum of the parts. Clin. Infect. Dis. 48:362-364.
13. Grossman, Z., M. Meier-Schellersheim, A. E. Sousa, R. M. Victorino, and W. E. Paul. 2002. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. 8:319-323. (Pubitemid 34407019)
14. Guo, Q., H. T. Ho, I. Dicker, L. Fan, N. Zhou, J. Friborg, T. Wang, B. V. McAuliffe, H. G. Wang, R. E. Rose, H. Fang, H. T. Scarnati, D. R. Langley, N. A. Meanwell, R. Abraham, R. J. Colonno, and P. F. Lin. 2003. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77:10528-10536. (Pubitemid 37129696)
15. Hammer, S. M., J. J. Eron, Jr., P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, and P. A. Volberding. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 300:555-570.
16. + T cells go out of stock. Nat. Immunol. 1:285-289.
17. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
18. Ho, H. T., L. Fan, B. Nowicka-Sans, B. McAuliffe, C. B. Li, G. Yamanaka, N. Zhou, H. Fang, I. Dicker, R. Dalterio, Y. F. Gong, T. Wang, Z. Yin, Y. Ueda, J. Matiskella, J. Kadow, P. Clapham, J. Robinson, R. Colonno, and P. F. Lin. 2006. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 80:4017-4025.
19. + T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J. Virol. 79:6299-6311.
20. Holm, G. H., C. Zhang, P. R. Gorry, K. Peden, D. Schols, E. De Clercq, and D. Gabuzda. 2004. Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J. Virol. 78:4541-4551.
21. Hung, C. S., S. Pontow, and L. Ratner. 1999. Relationship between productive HIV-1 infection of macrophages and CCR5 utilization. Virology 264:278-288.
22. Hunt, P. W., P. R. Harrigan, W. Huang, M. Bates, D. W. Williamson, J. M. McCune, R. W. Price, S. S. Spudich, H. Lampiris, R. Hoh, T. Leigler, J. N. Martin, and S. G. Deeks. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J. Infect. Dis. 194:926-930.
23. Kuritzkes, D. R. 2009. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 4:82-87.
24. + T-lymphocyte loss and is dependent on the tropism of the gp120 envelope glycoprotein. Virology 327:70-82.
25. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46:72-77.
26. Li, C. J., D. J. Freidman, C. Wang, V. Metelev, and A. B. Pardee. 1995. Induction of apoptosis in unifected lymphocytes by HIV-1 Yay protein. Science 268:429-431.
27. Lin, P. F., W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y. F. Gong, H. G. Wang, R. Rose, G. Yamanaka, B. Robinson, C. B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100:11013-11018.
28. Lum, J. J., D. J. Schnepple, and A. D. Badley. 2005. Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. AIDS 19:1125-1133.
29. Makinson, A., and J. Reynes. 2009. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr. Opin. HIV AIDS 4:150-158.
30. Martelli, A. M., M. Zweyer, R. L. Ochs, P. L. Tazzari, G. Tabellini, P. Narducci, and R. Bortul. 2001. Nuclear apoptotic changes: an overview. J. Cell. Biochem. 82:634-646.
31. + T-cell depletion in HIV disease. Nature 410:974-979.
32. McKnight, A., D. Wilkinson, G. Simmons, S. Talbot, L. Picard, M. Ahuja, M. Marsh, J. A. Hoxie, and P. R. Clapham. 1997. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71:1692-1696. (Pubitemid 27030351)
33. Monforte, A., D. Abrams, C. Pradier, R. Weber, P. Reiss, F. Bonnet, O. Kirk, M. Law, S. De Wit, N. Friis-Moller, A. N. Phillips, C. A. Sabin, and J. D. Lundgren. 2008. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22:2143-2153.
34. Moyle, G. J., A. Wildfire, S. Mandalia, H. Mayer, J. Goodrich, J. Whitcomb, and B. G. Gazzard. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872.
35. + T cell depletion in HIV-1-infected human lymphoid tissue. Proc. Natl. Acad. Sci. USA 96:663-668.
36. Piatak, M., Jr., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754. (Pubitemid 23114661)
37. Rogalinska, M. 2002. Alterations in cell nuclei during apoptosis. Cell. Mol. Biol. Lett. 7:995-1018.
38. Roggero, R., V. Robert-Hebmann, S. Harrington, J. Roland, L. Vergne, S. Jaleco, C. Devaux, and M. Biard-Piechaczyk. 2001. Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling. J. Virol. 75:7637-7650.
39. Silvestri, G. 2008. AIDS pathogenesis: a tale of two monkeys. J. Med. Primatol. 37(Suppl. 2):6-12.
40. Silvestri, G., D. L. Sodora, R. A. Koup, M. Paiardini, S. P. O'Neil, H. M. McClure, S. I. Staprans, and M. B. Feinberg. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18:441-452. (Pubitemid 36351522)
41. Smith, C. L., and G. E. Stein. 2002. Viral load as a surrogate end point in HIV disease. Ann. Pharmacother. 36:280-287.
42. Smyth, R. J., Y. Yi, A. Singh, and R. G. Collman. 1998. Determinants of entry cofactor utilization and tropism in a dual tropic human immunodeficiency virus type 1 primary isolate. J. Virol. 72:4478-4484.
43. Soriano, V., A. M. Geretti, C. F. Perno, G. Fatkenheuer, D. Pillay, J. Reynes, G. Tambussi, V. Calvez, J. Alcami, and J. Rockstroh. 2008. Optimal use of maraviroc in clinical practice. AIDS 22:2231-2240.
44. Squier, M. K., A. J. Sehnert, and J. J. Cohen. 1995. Apoptosis in leukocytes. J. Leukoc. Biol. 57:2-10.
45. Stewart, S. A., B. Poon, J. Y. Song, and I. S. Y. Chen. 2000. Human immunodeficiency virus type 1 Vpr induces apoptosis through caspase activation. J. Virol. 74:3105-3111. (Pubitemid 30143733)
46. Sullivan, N., Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Densilova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski. 1998. CD-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:4694-4703. (Pubitemid 28215644)
47. Vlahakis, S. R., A. Algeciras-Schimnich, G. Bou, C. J. Heppelmann, A. Villasis-Keever, R. C. Collman, and C. V. Paya. 2001. Chemokine-receptor activation by Env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J. Clin. Investig. 107:207-215.
48. Wang, B. Z., W. Liu, S. M. Kang, M. Alam, C. Huang, L. Ye, Y. Sun, Y. Li, D. L. Kothe, P. Pushko, T. Dokland, B. F. Haynes, G. Smith, B. H. Hahn, and R. W. Compans. 2007. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J. Virol. 81:10869-10878. (Pubitemid 47536061)
49. Wang, H. G., R. E. Williams, and P. F. Lin. 2004. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr. Pharm. Des. 10:1785-1793.
50. Wang, T., Z. Zhang, O. B. Wallace, M. Deshpande, H. Fang, Z. Yang, L. M. Zadjura, D. L. Tweedie, S. Huang, F. Zhao, S. Ranadive, B. S. Robinson, Y. F. Gong, K. Ricarrdi, T. P. Spicer, C. Deminie, R. Rose, H. G. Wang, W. S. Blair, P. Y. Shi, P. F. Lin, R. J. Colonno, and N. A. Meanwell. 2003. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46:4236-4239.
51. Waters, L., S. Mandalia, P. Randell, A. Wildfire, B. Gazzard, and G. Moyle. 2008. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin. Infect. Dis. 46:1617-1623.
52. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
53. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. M. Debatin, and P. H. Krammer. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497-500.
54. Wilkin, T. J., Z. Su, D. R. Kuritzkes, M. Hughes, C. Flexner, R. Gross, E. Coakley, W. Greaves, C. Godfrey, P. R. Skolnik, J. Timpone, B. Rodriguez, and R. M. Gulick. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. 44:591-595.
55. Yao, Q., R. W. Compans, and C. Chen. 2001. HIV envelope proteins differentially utilize CXCR4 and CCR5 coreceptors for induction of apoptosis. Virology 285:128-137. (Pubitemid 32589015)
56. Yi, Y., L. Loftin, L. Wang, S. J. Ratcliffe, J. Isaacman-Beck, and R. G. Collman. 2008. Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection. J. Acquir. Immune Defic. Syndr. 47:285-292.
57. Yuan, W., S. Craig, Z. Si, M. Farzan, and J. Sodroski. 2004. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J. Virol. 78:5448-5457. (Pubitemid 38581494)
58. Zhu, P., J. Liu, J. Bess, Jr., E. Chertova, J. D. Lifson, H. Grise, G. A. Ofek, K. A. Taylor, and K. H. Roux. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. (Pubitemid 43910414)